BioCentury
ARTICLE | Company News

Idea, Celtic Pharma deal

February 27, 2006 8:00 AM UTC

Celtic acquired a portfolio of dermatology products from Idea and licensed exclusive global rights to the German company's Transfersome transdermal delivery technology. Idea will receive an undisclosed upfront cash payment and is eligible for milestones and royalties. Under a September 2005 deal, Celtic holds a 21.7% stake in Idea (see BioCentury, Oct. 3, 2005).

The dermatology deal includes IDEA-070, which is in Phase II testing to treat skin pain and inflammation; IDEA-068/072, which is in Phase I testing to treat dermatitis and psoriasis; and IDEA-067, which is in preclinical testing to treat onychomycosis. ...